Northwest Biotherapeutics (OTCMKTS:NWBO – Get Rating) is one of 993 public companies in the "Pharmaceutical preparations" industry, but how does it compare to its competitors? We will compare Northwest Biotherapeutics to similar companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, dividends, profitability and risk.
Earnings and Valuation
This table compares Northwest Biotherapeutics and its competitors revenue, earnings per share and valuation.
Get Northwest Biotherapeutics alerts:| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Northwest Biotherapeutics | $1.68 million | -$105.03 million | -5.20 |
| Northwest Biotherapeutics Competitors | $1.81 billion | $241.52 million | -3.90 |
Northwest Biotherapeutics' competitors have higher revenue and earnings than Northwest Biotherapeutics. Northwest Biotherapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Northwest Biotherapeutics has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Northwest Biotherapeutics' competitors have a beta of 0.91, suggesting that their average stock price is 9% less volatile than the S&P 500.
Institutional & Insider Ownership
0.2% of Northwest Biotherapeutics shares are owned by institutional investors. Comparatively, 40.7% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 13.9% of Northwest Biotherapeutics shares are owned by company insiders. Comparatively, 15.6% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Northwest Biotherapeutics and its competitors' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Northwest Biotherapeutics | -6,240.76% | -50.86% | -348.36% |
| Northwest Biotherapeutics Competitors | -3,408.19% | -234.46% | -35.34% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Northwest Biotherapeutics and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Northwest Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
| Northwest Biotherapeutics Competitors | 4253 | 15151 | 41626 | 722 | 2.63 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 106.28%. Given Northwest Biotherapeutics' competitors higher possible upside, analysts plainly believe Northwest Biotherapeutics has less favorable growth aspects than its competitors.
Summary
Northwest Biotherapeutics competitors beat Northwest Biotherapeutics on 9 of the 10 factors compared.
About Northwest Biotherapeutics
(Get Rating)
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.